Celularity Inc. Logo

Celularity Inc.

GXGX

(0.8)
Stock Price

10,20 USD

-105.37% ROA

-119.53% ROE

-0.32x PER

Market Cap.

52.103.502,00 USD

159.71% DER

0% Yield

-72.72% NPM

Celularity Inc. Stock Analysis

Celularity Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Celularity Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.31x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a reasonable amount of debt compared to its ownership (52%), suggesting a balanced financial position and a moderate level of risk.

3 ROE

Negative ROE (-51.93%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-57.35%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Celularity Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Celularity Inc. Technical Stock Analysis
# Analysis Recommendation

Celularity Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Celularity Inc. Revenue
Year Revenue Growth
2018 17.554.000
2019 21.147.000 16.99%
2020 14.278.000 -48.11%
2021 21.335.000 33.08%
2022 17.975.000 -18.69%
2023 48.448.000 62.9%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Celularity Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2018 29.063.000
2019 46.051.000 36.89%
2020 52.707.000 12.63%
2021 88.353.000 40.34%
2022 78.363.000 -12.75%
2023 -1.088.000 7302.48%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Celularity Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 0
2019 564.339 100%
2020 30.572.000 98.15%
2021 71.089.000 56.99%
2022 65.858.000 -7.94%
2023 52.096.000 -26.42%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Celularity Inc. EBITDA
Year EBITDA Growth
2018 -1.100
2019 -1.683.540 99.93%
2020 -65.451.000 97.43%
2021 -96.927.000 32.47%
2022 -141.135.000 31.32%
2023 52.560.000 368.52%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Celularity Inc. Gross Profit
Year Gross Profit Growth
2018 10.999.000
2019 14.823.000 25.8%
2020 9.346.000 -58.6%
2021 11.682.000 20%
2022 -1.690.000 791.24%
2023 10.012.000 116.88%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Celularity Inc. Net Profit
Year Net Profit Growth
2018 -1.098
2019 5.878.770 100.02%
2020 -208.233.000 102.82%
2021 -100.118.000 -107.99%
2022 14.192.000 805.45%
2023 38.188.000 62.84%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Celularity Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 0
2019 2 100%
2020 -113 101.77%
2021 -15 -707.14%
2022 1 1500%
2023 2 50%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Celularity Inc. Free Cashflow
Year Free Cashflow Growth
2018 -1.918.543
2019 -32.672.833 94.13%
2020 -91.027.000 64.11%
2021 -116.299.000 21.73%
2022 -143.112.000 18.74%
2023 -4.921.000 -2808.19%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Celularity Inc. Operating Cashflow
Year Operating Cashflow Growth
2018 -543
2019 -1.097.833 99.95%
2020 -63.193.000 98.26%
2021 -110.096.000 42.6%
2022 -137.876.000 20.15%
2023 -4.341.000 -3076.13%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Celularity Inc. Capital Expenditure
Year Capital Expenditure Growth
2018 1.918.000
2019 31.575.000 93.93%
2020 27.834.000 -13.44%
2021 6.203.000 -348.72%
2022 5.236.000 -18.47%
2023 580.000 -802.76%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Celularity Inc. Equity
Year Equity Growth
2018 -125.847
2019 263.393.756 100.05%
2020 -531.400.000 149.57%
2021 99.418.000 634.51%
2022 198.901.000 50.02%
2023 40.960.000 -385.6%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Celularity Inc. Assets
Year Assets Growth
2018 24.707
2019 291.605.350 99.99%
2020 431.008.000 32.34%
2021 414.128.000 -4.08%
2022 401.066.000 -3.26%
2023 143.889.000 -178.73%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Celularity Inc. Liabilities
Year Liabilities Growth
2018 150.555
2019 28.211.594 99.47%
2020 962.408.000 97.07%
2021 314.710.000 -205.81%
2022 202.165.000 -55.67%
2023 102.929.000 -96.41%

Celularity Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.06
Net Income per Share
-7.43
Price to Earning Ratio
-0.32x
Price To Sales Ratio
2.77x
POCF Ratio
-1.78
PFCF Ratio
-2.12
Price to Book Ratio
1.03
EV to Sales
6.23
EV Over EBITDA
-5.36
EV to Operating CashFlow
-4.95
EV to FreeCashFlow
-4.78
Earnings Yield
-3.13
FreeCashFlow Yield
-0.47
Market Cap
0,05 Bil.
Enterprise Value
0,12 Bil.
Graham Number
19.6
Graham NetNet
-5.09

Income Statement Metrics

Net Income per Share
-7.43
Income Quality
0.18
ROE
-2.09
Return On Assets
-0.27
Return On Capital Employed
-0.3
Net Income per EBT
1
EBT Per Ebit
2.22
Ebit per Revenue
-0.33
Effective Tax Rate
0.38

Margins

Sales, General, & Administrative to Revenue
0.69
Research & Developement to Revenue
0.72
Stock Based Compensation to Revenue
0.59
Gross Profit Margin
0.64
Operating Profit Margin
-0.33
Pretax Profit Margin
-0.73
Net Profit Margin
-0.73

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.33
Free CashFlow per Share
-1.38
Capex to Operating CashFlow
-0.04
Capex to Revenue
0.04
Capex to Depreciation
0.12
Return on Invested Capital
-1.2
Return on Tangible Assets
-1.05
Days Sales Outstanding
234.82
Days Payables Outstanding
362.13
Days of Inventory on Hand
147.3
Receivables Turnover
1.55
Payables Turnover
1.01
Inventory Turnover
2.48
Capex per Share
0.05

Balance Sheet

Cash per Share
0,01
Book Value per Share
2,30
Tangible Book Value per Share
1.27
Shareholders Equity per Share
2.3
Interest Debt per Share
3.83
Debt to Equity
1.6
Debt to Assets
0.45
Net Debt to EBITDA
-2.98
Current Ratio
0.29
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
-0,08 Bil.
Invested Capital
49661000
Working Capital
-0,05 Bil.
Intangibles to Total Assets
0.13
Average Receivables
0,01 Bil.
Average Payables
0,01 Bil.
Average Inventory
5343500
Debt to Market Cap
1.26

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Celularity Inc. Dividends
Year Dividends Growth

Celularity Inc. Profile

About Celularity Inc.

GX Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company is not engaged in any business operations and it has not generated any revenue.

CEO
Mr. Jay R. Bloom
Employee
0
Address
1325 Avenue of the Americas Fl 25
New York City, 10019

Celularity Inc. Executives & BODs

Celularity Inc. Executives & BODs
# Name Age

Celularity Inc. Competitors